Systemic sclerosis endothelial cells recruit and activate dermal fibroblasts by induction of a connective tissue growth factor (CCN2)/ transforming growth factor β-dependent mesenchymal-to-mesenchymal transition

Arthritis and Rheumatism

Volumn 65, Issue 1, 2013, Pages 258-269

  Serratì, Simona ^a,b   Chillà, Anastasia ^a   Laurenzana, Anna ^a   Margheri, Francesca ^a   Giannoni, Elisa ^a   Magnelli, Lucia ^a   Chiarugi, Paola ^a   Dotor, Javier ^c   Feijoo, Esperanza ^c   Bazzichi, Laura ^d   Bombardieri, Stefano ^d   Kahaleh, Bashar ^e   Fibbi, Gabriella ^a   Del Rosso, Mario ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c Digna Biotech   (Spain)

^d UNIVERSITY OF PISA   (Italy)

^e MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY; GELATINASE A; GELATINASE B; GUANOSINE TRIPHOSPHATASE; MATRIGEL; MATRIX METALLOPROTEINASE; PEPTIDE P17; RAC1 PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; UNCLASSIFIED DRUG; VIMENTIN;

ARTICLE; ASSAY; CELL ACTIVATION; CELL INVASION; CELL MOTILITY; CELL TRANSFORMATION; CULTURE MEDIUM; ENZYME ACTIVATION; ENZYME INHIBITION; FIBROBLAST; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MESENCHYMAL TO MESENCHYMAL TRANSITION; MICROVASCULAR ENDOTHELIAL CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS; WESTERN BLOTTING; ZYMOGRAPHY;

BLOTTING, WESTERN; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; DRUG COMBINATIONS; ENDOTHELIAL CELLS; FEMALE; FIBROBLASTS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LAMININ; MALE; MESODERM; PROTEOGLYCANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SKIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84871807839     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37705     Document Type: Article

References (34)

1. LeRoy EC,. Systemic sclerosis: a vascular perspective. Rheum Dis Clin North Am 1996; 22: 675-94.
2. Kahaleh MB,. The role of vascular endothelium in fibroblast activation and tissue fibrosis, particularly in scleroderma (systemic sclerosis) and pachydermoperiostosis (primary hypertrophic osteoarthropathy). Clin Exp Rheumatol 1992; 10: 51-6.
3. Abraham DJ, Krieg T, Distler J, Distler O,. Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2009; 48: 3-7.
4. Katsumoto TR, Whitfield ML, Connolly MK,. The pathogenesis of systemic sclerosis. Annu Rev Pathol 2011; 6: 509-37.
5. D'Alessio S, Fibbi G, Cinelli M, Guiducci S, Del Rosso A, Margheri F, et al. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum 2004; 50: 3275-85.
6. Giusti B, Serrati S, Margheri F, Papucci L, Rossi L, Poggi F, et al. The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. Arthritis Rheum 2005; 52: 3618-28.
7. Giusti B, Fibbi G, Margheri F, Serrati S, Rossi L, Poggi F, et al. A model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients. Arthritis Res Ther 2006; 8: R115.
8. Serrati S, Cinelli M, Margheri F, Guiducci S, Del Rosso A, Pucci M, et al. Systemic sclerosis fibroblasts inhibit in vitro angiogenesis by MMP-12-dependent cleavage of the endothelial cell urokinase receptor. J Pathol 2006; 210: 240-8.
9. Margheri F, Manetti M, Serrati S, Nosi D, Pucci M, Matucci-Cerinic M, et al. Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, β2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells. Arthritis Rheum 2006; 54: 3926-38.
10. Margheri F, Serrati S, Lapucci A, Chilla A, Bazzichi L, Bombardieri S, et al. Modulation of the angiogenic phenotype of normal and systemic sclerosis endothelial cells by gain-loss of function of pentraxin 3 and matrix metalloproteinase 12. Arthritis Rheum 2010; 62: 2488-98.
11. Shimo T, Nakanishi T, Nishida T, Asano M, Kanyama M, Kuboki T, et al. Connective tissue growth factor induces the proliferation, migration, and tube formation of vascular endothelial cells in vitro, and angiogenesis in vivo. J Biochem 1999; 126: 137-45.
12. Leask A, Abraham DJ,. The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem Cell Biol 2003; 81: 355-63.
13. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
14. Dotor J, Lopez-Vazquez AB, Lasarte JJ, Sarobe P, Garcia-Granero M, Riezu-Boj JI, et al. Identification of peptide inhibitors of transforming growth factor β1 using a phage-displayed peptide library. Cytokine 2007; 39: 106-15.
15. Ezquerro IJ, Lasarte JJ, Dotor J, Castilla-Cortazar I, Bustos M, Penuelas I, et al. A synthetic peptide from transforming growth factor β type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury. Cytokine 2003; 22: 12-20.
16. Fibbi G, Pucci M, Grappone C, Pellegrini G, Salzano R, Casini A, et al. Functions of the fibrinolytic system in human Ito cells and its control by basic fibroblast and platelet-derived growth factor. Hepatology 1999; 29: 868-78.
17. Margheri F, Chilla A, Laurenzana A, Serrati S, Mazzanti B, Saccardi R, et al. Endothelial progenitor cell-dependent angiogenesis requires localization of the full-length form of uPAR in caveolae. Blood 2011; 118: 3743-55.
18. Abraham D,. Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc? [review]. Rheumatology (Oxford) 2008; 47 Suppl 5: v8-9.
19. Grande MT, Lopez-Novoa JM,. Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat Rev Nephrol 2009; 5: 319-28.
20. Leask A, Abraham DJ,. TGF-β signaling and the fibrotic response. FASEB J 2004; 18: 816-27.
21. Cat B, Stuhlmann D, Steinbrenner H, Alili L, Holtkotter O, Sies H, et al. Enhancement of tumor invasion depends on transdifferentiation of skin fibroblasts mediated by reactive oxygen species. J Cell Sci 2006; 119: 2727-38.
22. Zhang YE,. Non-Smad pathways in TGF-β signaling. Cell Res 2009; 19: 128-39.
23. Friedl P,. Prespecification and plasticity: shifting mechanisms of cell migration. Curr Opin Cell Biol 2004; 16: 14-23.
24. Wolf K, Mazo I, Leung H, Engelke K, von Andrian UH, Deryugina EI, et al. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol 2003; 160: 267-77.
25. Parri M, Taddei ML, Bianchini F, Calorini L, Chiarugi P,. EphA2 reexpression prompts invasion of melanoma cells shifting from mesenchymal to amoeboid-like motility style. Cancer Res 2009; 69: 2072-81.
26. Friedl P, Wolf K,. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003; 3: 362-74.
27. Yamazaki D, Kurisu S, Takenawa T,. Regulation of cancer cell motility through actin reorganization. Cancer Sci 2005; 96: 379-86.
28. Serrati S, Margheri F, Pucci M, Cantelmo AR, Cammarota R, Dotor J, et al. TGFβ1 antagonistic peptides inhibit TGFβ1-dependent angiogenesis. Biochem Pharmacol 2009; 77: 813-25.
29. Shi-Wen X, Leask A, Abraham D,. Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. Cytokine Growth Factor Rev 2008; 19: 133-44.
30. Abreu JG, Ketpura NI, Reversade B, De Robertis EM,. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-β. Nat Cell Biol 2002; 4: 599-604.
31. Mori T, Kawara S, Shinozaki M, Hayashi N, Kakinuma T, Igarashi A, et al. Role and interaction of connective tissue growth factor with transforming growth factor-β in persistent fibrosis: a mouse fibrosis model. J Cell Physiol 1999; 181: 153-9.
32. Trojanowska M,. Noncanonical transforming growth factor β signaling in scleroderma fibrosis. Curr Opin Rheumatol 2009; 21: 623-9.
33. Zavadil J, Bottinger EP,. TGF-β and epithelial-to-mesenchymal transitions. Oncogene 2005; 24: 5764-74.
34. Leask A,. Possible strategies for anti-fibrotic drug intervention in scleroderma. J Cell Commun Signal 2011; 5: 125-9.